NO761306L - - Google Patents
Info
- Publication number
- NO761306L NO761306L NO761306A NO761306A NO761306L NO 761306 L NO761306 L NO 761306L NO 761306 A NO761306 A NO 761306A NO 761306 A NO761306 A NO 761306A NO 761306 L NO761306 L NO 761306L
- Authority
- NO
- Norway
- Prior art keywords
- glycoprotein
- pregnancy
- specific
- solution
- value
- Prior art date
Links
- 230000035935 pregnancy Effects 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 210000002826 placenta Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 17
- 239000003463 adsorbent Substances 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- -1 NaNO^ Chemical class 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- CGMRCMMOCQYHAD-UHFFFAOYSA-J dicalcium hydroxide phosphate Chemical compound [OH-].[Ca++].[Ca++].[O-]P([O-])([O-])=O CGMRCMMOCQYHAD-UHFFFAOYSA-J 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- YYXLGGIKSIZHSF-UHFFFAOYSA-N ethene;furan-2,5-dione Chemical compound C=C.O=C1OC(=O)C=C1 YYXLGGIKSIZHSF-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/569,476 US4065445A (en) | 1971-09-29 | 1975-04-18 | Pregnancy-specific β1 -glycoprotein and process for isolating it |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO761306L true NO761306L (fi) | 1976-10-19 |
Family
ID=24275609
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO761306A NO761306L (fi) | 1975-04-18 | 1976-04-14 | |
| NO761305A NO145405C (no) | 1975-04-18 | 1976-04-14 | Fremgangsmaate til rensning av det svangerskapsspesifikke beta-1-glykoprotein |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO761305A NO145405C (no) | 1975-04-18 | 1976-04-14 | Fremgangsmaate til rensning av det svangerskapsspesifikke beta-1-glykoprotein |
Country Status (18)
| Country | Link |
|---|---|
| JP (2) | JPS51133406A (fi) |
| AT (2) | AT344920B (fi) |
| AU (2) | AU503342B2 (fi) |
| BE (2) | BE840912A (fi) |
| CA (2) | CA1065305A (fi) |
| DE (1) | DE2612479A1 (fi) |
| DK (2) | DK173576A (fi) |
| ES (2) | ES446944A1 (fi) |
| FI (2) | FI56184C (fi) |
| FR (2) | FR2307816A1 (fi) |
| GB (2) | GB1541454A (fi) |
| IE (2) | IE42566B1 (fi) |
| IT (1) | IT1060215B (fi) |
| LU (2) | LU74782A1 (fi) |
| NL (2) | NL7603903A (fi) |
| NO (2) | NO761306L (fi) |
| NZ (1) | NZ180619A (fi) |
| SE (2) | SE7604483L (fi) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2720704C2 (de) * | 1977-05-07 | 1986-09-25 | Behringwerke Ag, 3550 Marburg | Neues Glycoprotein, Verfahren zu seiner Herstellung und seine Verwendung |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5325030B2 (fi) * | 1972-12-19 | 1978-07-24 |
-
1976
- 1976-03-24 DE DE19762612479 patent/DE2612479A1/de active Pending
- 1976-04-12 ES ES446944A patent/ES446944A1/es not_active Expired
- 1976-04-12 ES ES446939A patent/ES446939A1/es not_active Expired
- 1976-04-13 NL NL7603903A patent/NL7603903A/xx not_active Application Discontinuation
- 1976-04-13 NL NL7603902A patent/NL7603902A/xx not_active Application Discontinuation
- 1976-04-14 NO NO761306A patent/NO761306L/no unknown
- 1976-04-14 FI FI761017A patent/FI56184C/fi not_active IP Right Cessation
- 1976-04-14 NO NO761305A patent/NO145405C/no unknown
- 1976-04-14 FI FI761016A patent/FI54486C/fi not_active IP Right Cessation
- 1976-04-14 DK DK173576A patent/DK173576A/da active IP Right Grant
- 1976-04-14 DK DK173876A patent/DK173876A/da active IP Right Grant
- 1976-04-15 SE SE7604483A patent/SE7604483L/ not_active Application Discontinuation
- 1976-04-15 SE SE7604484A patent/SE419340B/xx unknown
- 1976-04-15 CA CA250,426A patent/CA1065305A/en not_active Expired
- 1976-04-15 GB GB15558/76A patent/GB1541454A/en not_active Expired
- 1976-04-15 GB GB15557/76A patent/GB1541453A/en not_active Expired
- 1976-04-15 AU AU13082/76A patent/AU503342B2/en not_active Expired
- 1976-04-15 NZ NZ180619A patent/NZ180619A/xx unknown
- 1976-04-15 AU AU13081/76A patent/AU503288B2/en not_active Expired
- 1976-04-15 CA CA250,439A patent/CA1065307A/en not_active Expired
- 1976-04-15 IE IE817/76A patent/IE42566B1/en unknown
- 1976-04-15 IE IE818/76A patent/IE42679B1/en unknown
- 1976-04-16 AT AT284176A patent/AT344920B/de not_active IP Right Cessation
- 1976-04-16 LU LU74782A patent/LU74782A1/xx unknown
- 1976-04-16 IT IT22445/76A patent/IT1060215B/it active
- 1976-04-16 AT AT284276A patent/AT344734B/de not_active IP Right Cessation
- 1976-04-16 FR FR7611372A patent/FR2307816A1/fr active Granted
- 1976-04-16 FR FR7611367A patent/FR2307815A1/fr active Granted
- 1976-04-16 LU LU74783A patent/LU74783A1/xx unknown
- 1976-04-17 JP JP51044152A patent/JPS51133406A/ja active Granted
- 1976-04-17 JP JP51044151A patent/JPS51133408A/ja active Pending
- 1976-04-20 BE BE166290A patent/BE840912A/xx unknown
- 1976-04-20 BE BE166291A patent/BE840913A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0083483B1 (en) | Ultrapurificated factor viii : c preparation | |
| US4138287A (en) | Purifying and isolating method for hepatitis virus to use in preparing vaccine | |
| US4465624A (en) | Process for producing erythropoietin | |
| US4181713A (en) | Isolation of HBs Ag | |
| CZ277939B6 (en) | Process for preparing stable concentrate of a complex factor viii-von willebrand factor exhibiting high specific activity | |
| GB2179947A (en) | Process for the extraction of proteins from milk | |
| US6001974A (en) | Method of separating albumin from serum by ion-exchange chromatography with membrane adsorbers | |
| JPH0533239B2 (fi) | ||
| US4247452A (en) | Purification of pertussis haemagglutinins | |
| US5055557A (en) | Ultrapurification of factor IX and other vitamin K-dependent proteins | |
| CA1101847A (en) | Process for the concentration of a placenta-specific glycoprotein | |
| US4065445A (en) | Pregnancy-specific β1 -glycoprotein and process for isolating it | |
| CA1252744A (en) | Ultrapurification of factor ix and other vitamin k- dependent proteins | |
| NO761306L (fi) | ||
| NO142961B (no) | Steroidbindende globulin til anvendelse ved in vitro-diagnostikk og ved fremstilling av antisera | |
| WO1998054195A1 (en) | Large-scale isolation and purification of hif | |
| CA1151542A (en) | Process for preparing the third component of the complement from human blood plasma | |
| US4859766A (en) | Purified appetite-regulating substances of biological orgin, their antibodies, immunocomplexes of the appetite--regulating substances formed with the antibodies and processes for preparing same | |
| JPS5810522A (ja) | 不活化トロンビンゲルによるアンチトロンビン３の精製法 | |
| JPH03157396A (ja) | ペクチン酸―セルロースゲルによる蛋白質分離方法 | |
| Mattiasson | Membrane affinity filtration | |
| JPH0348697A (ja) | 濃縮・精製された上皮細胞成長因子の製造法 | |
| JPS6141548B2 (fi) | ||
| EP0217061A1 (en) | Ultrapurification of factor VIII | |
| JPS59164727A (ja) | Ｂ型肝炎ウイルス表面抗原の精製方法 |